Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

letter

. 2023 Apr 21;11:43. doi: 10.1186/s40364-023-00479-4

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 1 — METTL3 inhibits EC by promoting immunosurveillance. A The endometria from endometrial tissues microarray cohort was subjected to IHC analysis to determine METTL3 level (scale bar: 100 μm; **P < 0.01 vs. Normal group). B The protein and mRNA expressions of METTL3 in endometria from normal subjects and EC patients (n = 3, **P < 0.01 vs. Normal group). C METTL3 expression in EC form TCGA datasets (****P < 0.0001 vs. Normal group). D Kaplan-Meier curves of correlation of METTL3 with the EC cumulative survival from endometrial tissues microarray cohort (P = 0.04) and TCGA datasets (P < 0.001). E The endometria from endometrial tissues microarray cohort was subjected to IHC analysis to determine CD8 level (scale bar: 100 μm; **P < 0.01 vs. Normal group). F Expression correlation between METTL3 and CD8 in endometrial tissues microarray cohort by Pearson correlation analysis (R = 0.78, P < 2.2e-16). G The protein and mRNA expressions of METTL3 in HEC-1 A, HEC-1B, and Ishikawa cell. H The protein and mRNA expressions of METTL3 in Ishikawa cell with or without METTL3 overexpression (**P < 0.01 vs. Vector group). I The protein and mRNA expressions of METTL3 in HEC-1 A and HEC-1B cell with or without shMETTL3 (**P < 0.01 vs. shNC group). J The proliferation of CD8⁺ T cell in co-cultured system (**P < 0.01 vs. shNC group, ^##P < 0.01 vs. Vector group). K The proliferation of HEC-1 A, HEC-1B, and Ishikawa cell in co-cultured system (*P < 0.05 vs. shNC group, **P < 0.01 vs. shNC group, ^##P < 0.01 vs. Vector group). L The apoptosis of HEC-1 A, HEC-1B, and Ishikawa cell in co-cultured system (**P < 0.01 vs. shNC group, ^##P < 0.01 vs. Vector group). M The migration of HEC-1 A, HEC-1B, and Ishikawa cell in co-cultured system (scale bar: 100 μm; **P < 0.01 vs. shNC group, ^##P < 0.01 vs. Vector group). N Representative images of xenograft tumors in BALB/C female mice by Ishikawa cell transfected with or without METTL3 overexpression. O Average tumor volume of BALB/C female mice (**P < 0.01 vs. Vector group). P Average tumor weight of BALB/C female mice (**P < 0.01 vs.vector group). Q Frequency of CD8⁺ T cell in the peripheral blood of BALB/C female mice (**P < 0.01 vs. Vector group). R IHC staining of METTL3 and CD8 in solid tumor of BALB/C female mice (scale bar: 100 μm; **P < 0.01 vs. Vector group)